Lung Cancer: Lung Cancer II |

Photodynamic Therapy for Patients With Endobronchial Carcinoid FREE TO VIEW

Gregory Loewen, DO; Robert Cerfolio, PhD; Ayesha Bryant, MD; Brian Pettiford, MD; Tracy Roundy, BS; Patsy Skabla, PA; Patrick Ross, MD
Author and Funding Information

Washington State University, Spokane, WA

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):706A. doi:10.1016/j.chest.2016.08.801
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Photodynamic therapy (PDT) has been used successfully in patients with endobronchial non-small cell lung cancer (NSCLC) with curative and palliative intent. We assessed outcomes of PDT in patients with endobronchial carcinoid.

METHODS: This is a records review using a multi-center registry that consists of patients who received endobronchial PDT for curative intent or for management of pulmonary symptoms. We evaluated adverse events and clinical outcomes including survival. All patients received porfimer sodium at 1-2 mg/kg intravenously as the photosensitizer. Light was administered at 630 nm for a total dose of 200 J, except for one case as noted below.

RESULTS: 1998 and 2014, 893 patients were treated with 1061 courses of PDT for esophageal and lung malignancies at 5 centers. Endobronchial PDT accounted for 530 of the cases. 9 patients received PDT for treatment of endobronchial carcinoid. Endobronchial therapy was offered when surgical resection could not be performed. 7/9 patients responded to PDT, and 4/9 exhibited patholocial complete responses with absence of tumor on repeat bronchoscopy. 1 patient with bulky disease at the carina was treated with 500J, responded poorly, and developed tracheoesophageal fistula postoperatively. 1 patient with multifocal disease required short term ventilator support. There were no post procedure deaths. Massive hemoptysis was not observed.

CONCLUSIONS: Endobronchial carcinoid can be ablated with PDT. Endobronchial PDT with porfimer sodium is generally well-tolerated with minimal morbidity. Significant hemoptysis was not observed even in the setting of multiple endobronchial manipulations of the tumor. Light dosage greater than 200J should be avoided. Tumor response to PDT was seen in 7/9 cases (77%), and this led to a pathological complete response in 4/9 (44%).

CLINICAL IMPLICATIONS: Carcinoid tumors are responsive to treatment with PDT. PDT should be considered for endobronchial treatment of carcinoid when surgical resection is not an option.

DISCLOSURE: Gregory Loewen: Consultant fee, speaker bureau, advisory committee, etc.: Pinnacle Biologics Inc Robert Cerfolio: Consultant fee, speaker bureau, advisory committee, etc.: Pinnacle Biologics, Inc. Patsy Skabla: Consultant fee, speaker bureau, advisory committee, etc.: Pinnacle Biologics, Inc. Patrick Ross: Grant monies (from industry related sources): Pinnacle Biologics, Inc., Consultant fee, speaker bureau, advisory committee, etc.: Pinnacle Biologics, Inc. The following authors have nothing to disclose: Ayesha Bryant, Brian Pettiford, Tracy Roundy

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543